RNXT

RenovoRx, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website renovorx.com
Employees(FY) 10
ISIN US75989R1077

Performance

+1.86%

1W

+21.27%

1M

-0.72%

3M

+118.88%

6M

-40.17%

YTD

-34.76%

1Y

Profile

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. The company was founded in 2009 and is headquartered in Los Altos, California.

Advanced Technical Analysis

Technical Analysis of RNXT 2024-05-10

Overview:

In analyzing the technical indicators for RNXT over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming days.

Trend Analysis:

...

See more ...

Recent News & Updates

2024-05-13 21:00
RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024(Businesswire)
2024-05-12 21:53
RNXT Stock Earnings: RenovoRx Beats EPS for Q1 2024(Investorplace)
2024-05-01 21:00
RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024(Businesswire)
2024-04-17 20:30
RenovoRx Regains Compliance with Nasdaq Stockholders Equity Requirement(Businesswire)
2024-04-15 20:30
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting(Businesswire)
2024-04-14 20:00
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026(Businesswire)
2024-04-08 01:52
RNXT Stock Earnings: RenovoRx Meets EPS for Q4 2023(Investorplace)
2024-04-07 20:30
RenovoRx Announces $11.1 Million at Market Private Placement(Businesswire)
2024-04-04 20:30
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024(Businesswire)
2024-03-11 21:00
RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024(Businesswire)
2024-03-08 03:05
RenovoRx Highlights Key Leadership Promotions(Businesswire)
2024-02-05 19:30
RenovoRx CEO Issues Letter to Shareholders(Businesswire)
2024-01-28 19:30
RenovoRx Closes $6.1 Million Private Placement(Businesswire)
2023-12-20 19:30
RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer(Businesswire)
2023-12-18 19:30
RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting(Businesswire)
2023-12-12 19:31
RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform(Businesswire)
2023-11-15 19:35
RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.(Businesswire)
2023-11-13 19:30
RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights(Businesswire)
2023-10-01 20:30
RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023(Businesswire)
2023-08-16 20:30
RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights(Yahoo Finance)
2023-07-30 20:30
RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference(Yahoo Finance)
2023-07-19 20:00
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP) Platform(Yahoo Finance)
2023-06-28 23:42
RenovoRx encountering "a lot of enthusiasm" for innovative cancer platform(Yahoo Finance)
2023-06-28 20:00
RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer(Yahoo Finance)
2023-06-19 20:30
RenovoRx Appoints Margaret A. Tempero, M.D., to Scientific Advisory Board(Yahoo Finance)
2023-06-11 20:30
RenovoRx Announces ROTH Capital Key Opinion Leader (KOL) Webcast on June 15(Yahoo Finance)
2023-05-31 20:30
RenovoRx Initiates Patient Enrollment at University of Texas Southwestern Medical Center for Pivotal Phase III TIGeR-PaC Clinical Trial(Yahoo Finance)
2023-05-24 20:30
RenovoRx Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer(Yahoo Finance)
2023-05-23 20:30
RenovoRx to Present at the LD Micro Invitational XIII Conference(Yahoo Finance)
2023-05-14 20:30
RenovoRx Reports First Quarter 2023 Financial Results and Operational Highlights(Yahoo Finance)

Page 1 of 3

previousnext